Table 1.

Estriol treatment ameliorates experimental autoimmune encephalomyelitis

ExperimentEAE/totalMean day of onsetMean score, all daysMean score, at death
Eight separate groups of mice were treated with placebo or 90-day-release hormone pellets (estriol or progesterone) before the induction of adoptive experimental autoimmune encephalomyelitis (EAE) with 18.5-kDa myelin basic protein-specific T lymphocytes. The incidence (EAE/total), mean day of onset, mean clinical scores over all days (repeated-measures analysis of variance), and mean clinical scores at day of sacrifice are demonstrated for mice receiving each treatment within each group. Three different doses of estriol were used: 5, 15, and 30 mg. Two different doses of progesterone were used: 15 and 50 mg.
* p < 0.05.
p < 0.005. Levels of significance between mean clinical scores in the indicated treatment group compared with the placebo treatment group in each experiment.
Experiment 1Day 10
Placebo (n = 4)4 /462.34.0
Estriol 15 mg (n = 5)4 /580.72.2*
Estriol 5 mg (n = 5)4 /571.32.4*
Experiment 2Day 24
Placebo (n = 5)4 /561.82.2
Estriol 15 mg (n = 5)5 /560.6*0.4*
Estriol 5 mg (n = 5)5 /570.3*0.0
Experiment 3Day 28
Placebo (n = 4)4 /473.23.7
Estriol 15 mg (n = 5)3 /591.11.0
Estriol 5 mg (n = 5)3 /591.3*1.5*
Experiment 4Day 24
Placebo (n = 5)4 /572.02.7
Estriol 30 mg (n = 5)1 /580.2*0.0*
Estriol 5 mg (n = 5)2 /590.4*0.2*
Experiment 5Day 20
Placebo (n = 5)5 /582.33.4
Estriol 15 mg (n = 4)4 /4111.22.2*
Progesterone 15 mg (n = 5)5 /592.22.9
Experiment 6Day 20
Placebo (n = 5)5 /572.92.8
Estriol 15 mg (n = 4)3 /4100.8*0.6
Progesterone 15 mg (n = 3)2 /362.01.8
Experiment 7Day 18
Placebo (n = 4)4 /463.93.8
Estriol 15 mg (n = 4)4 /4101.6*2.0*
Progesterone 15 mg (n = 4)4 /463.73.8
Experiment 8Day 22
Placebo (n = 3)3 /362.92.7
Estriol 15 mg (n = 3)2 /361.4*0.8*
Progesterone 50 mg (n = 4)4 /462.92.6